I-Derm develops a nonsteroidal topical treatment for inflammatory skin diseases based on a novel mechanism of action.

This mechanism directly targets cutaneous elements rather than the immune system and is therefore uniquely functional only on the skin.

This novel treatment is targeted as a nonsteroidal topical treatment for psoriasis.The molecule, CPT-11, up-regulates SAMD9, which in turn down-regulates EGR1, a critical regulator of inflammatory responses of the skin, in a dose-dependent manner.